Page last updated: 2024-12-06

glycosine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

glycosine: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID63123
CHEMBL ID448122
CHEBI ID2803
SCHEMBL ID1150473
MeSH IDM0062230

Synonyms (34)

Synonym
glycosin
nsc127745
nsc-127745
arborin
4(1h)-quinazolinone, 1-methyl-2-(phenylmethyl)-
4(1h)-quinazolinone, 2-benzyl-1-methyl-
mls002919960 ,
6873-15-0
glycosine
arborine
smr001797559
2-benzyl-1-methylquinazolin-4-one
chebi:2803 ,
CHEMBL448122
unii-d5juh3hnwf
nsc 127745
1-methyl-2-(phenylmethyl)-4(1h)-quinazolinone
d5juh3hnwf ,
glycosine [mi]
2-benzyl-1-methylquinazol-4-one
2-benzyl-1-methylquinazolin-4(1h)-one
SCHEMBL1150473
DTXSID10218856
AKOS024258266
2-benzyl-1-methyl-1,4-dihydroquinazolin-4-one
2-benzyl-1-methyl-4(1h)-quinazolinone
4(1h)-quinazolinone, 2-benzyl-1-methyl- (8ci)
4(1h)-quinazolinone, 1-methyl-2-(phenylmethyl)- (9ci)
1-methyl-2-(phenylmethyl)quinazolin-4-one
Q27105821
CS-0101513
HY-N7004
MS-23544
A866991
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
quinazolinesAny organic heterobicyclic compound based on a quinazoline skeleton and its substituted derivatives.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (17)

Assay IDTitleYearJournalArticle
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID333232Inhibition of TPA-induced EBV-early antigen activation in human Raji cells at 16 nM after 48 hrs relative to control2004Journal of natural products, Sep, Volume: 67, Issue:9
Chemical constituents of Glycosmis arborea: three new carbazole alkaloids and their biological activity.
AID333235Cytotoxicity against human Raji cells at 3.2 nM after 48 hrs by trypan blue staining method2004Journal of natural products, Sep, Volume: 67, Issue:9
Chemical constituents of Glycosmis arborea: three new carbazole alkaloids and their biological activity.
AID333230Inhibition of TPA-induced EBV-early antigen activation in human Raji cells at 32 nM after 48 hrs relative to control2004Journal of natural products, Sep, Volume: 67, Issue:9
Chemical constituents of Glycosmis arborea: three new carbazole alkaloids and their biological activity.
AID333234Inhibition of TPA-induced EBV-early antigen activation in human Raji cells at 3.2 nM after 48 hrs relative to control2004Journal of natural products, Sep, Volume: 67, Issue:9
Chemical constituents of Glycosmis arborea: three new carbazole alkaloids and their biological activity.
AID333231Cytotoxicity against human Raji cells at 32 nM after 48 hrs by trypan blue staining method2004Journal of natural products, Sep, Volume: 67, Issue:9
Chemical constituents of Glycosmis arborea: three new carbazole alkaloids and their biological activity.
AID333236Inhibition of TPA-induced EBV-early antigen activation in human Raji cells at 0.32 nM after 48 hrs relative to control2004Journal of natural products, Sep, Volume: 67, Issue:9
Chemical constituents of Glycosmis arborea: three new carbazole alkaloids and their biological activity.
AID333237Cytotoxicity against human Raji cells at 0.32 nM after 48 hrs by trypan blue staining method2004Journal of natural products, Sep, Volume: 67, Issue:9
Chemical constituents of Glycosmis arborea: three new carbazole alkaloids and their biological activity.
AID333233Cytotoxicity against human Raji cells at 16 nM after 48 hrs by trypan blue staining method2004Journal of natural products, Sep, Volume: 67, Issue:9
Chemical constituents of Glycosmis arborea: three new carbazole alkaloids and their biological activity.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (11)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (27.27)18.7374
1990's0 (0.00)18.2507
2000's4 (36.36)29.6817
2010's3 (27.27)24.3611
2020's1 (9.09)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 47.58

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index47.58 (24.57)
Research Supply Index2.48 (2.92)
Research Growth Index4.02 (4.65)
Search Engine Demand Index72.10 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (47.58)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other11 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]